Literature DB >> 2999228

Cross-reactions of immunoglobulin M and G antibodies with enterovirus-specific viral structural proteins.

F Reigel, F Burkhardt, U Schilt.   

Abstract

We analysed the reactivity of enterovirus-specific human IgM and IgG antibodies with the structural proteins of different enteroviruses by the immunoblot technique. In general, all immunoglobulin G antibodies of the tested sera reacted with capsid polypeptide VP 1 of the viruses tested (echoviruses 9 and 11, coxsackievirus B3 and poliovirus 2). In contrast, enterovirus specific immunoglobulin M antibodies of adults reacted with capsid polypeptides VP 1, VP 2, and/or VP 3 of the viruses mentioned above. The reactions with VP 2 and/or VP 3 were often stronger than with VP 1. IgM antibodies from sera of newborns infected by echovirus 11 reacted with VP 1 and VP 2/3 of echovirus 11 and also with VP 2 and VP 3 of poliovirus 2. Preabsorption experiments indicate that cross-reactive IgG antibodies react with epitopes of VP 1 not present on the surface of intact virus particles. The results from the immunoblot technique were compared to data from microneutralization tests and M-antibody capture radioimmunoassays.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999228      PMCID: PMC2129535          DOI: 10.1017/s0022172400062896

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  30 in total

1.  Homologous and heterologous complement fixing antibody in persons infected with ECHO; Coxsackie and poliomyelitis viruses.

Authors:  P HALONEN; L ROSEN; R J HUEBNER
Journal:  Proc Soc Exp Biol Med       Date:  1959-06

2.  Hemagglutination-inhibiting, complement-fixing and neutralizing antibody responses in ECHO 6 infection, including studies on heterotypic responses.

Authors:  R H BUSSELL; D T KARZON; A L BARRON; F T HALL
Journal:  J Immunol       Date:  1962-01       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Immunological studies of the group B coxsackieviruses by the sandwich enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation.

Authors:  M G Katze; R L Crowell
Journal:  J Gen Virol       Date:  1980-10       Impact factor: 3.891

5.  Coxsackie-B-virus-specific IgM responses in patients with cardiac and other diseases.

Authors:  M M El-Hagrassy; J E Banatvala; D J Coltart
Journal:  Lancet       Date:  1980-11-29       Impact factor: 79.321

6.  [Sensitive virologic evaluation in suspected meningitis: study of a radioimmunotest for the detection of IgM antibodies against ECHO 9 and ECHO 11 viruses].

Authors:  F Burkhardt; F Reigel; U Schilt
Journal:  Schweiz Med Wochenschr       Date:  1983-06-25

7.  Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization.

Authors:  E A Emini; P Ostapchuk; E Wimmer
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

8.  Immunochemical studies of polioviruses: identification of immunoreactive virus capsid polypeptides.

Authors:  R Thorpe; P D Minor; A Mackay; G C Schild; M Spitz
Journal:  J Gen Virol       Date:  1982-12       Impact factor: 3.891

9.  Indirect and reverse radioimmunoassays and their apparent specificities in the detection of antibodies to enteroviruses in human sera.

Authors:  E G Torfason; G Frisk; H Diderholm
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

10.  Specificity of IgM antibodies in acute human coxsackievirus B infections, analysed by indirect solid phase enzyme immunoassay and immunoblot technique.

Authors:  R Dörries; V ter Meulen
Journal:  J Gen Virol       Date:  1983-01       Impact factor: 3.891

View more
  1 in total

1.  Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides.

Authors:  J Cello; A Samuelson; P Stålhandske; B Svennerholm; S Jeansson; M Forsgren
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.